Immuneering Corporation (IMRX)
NASDAQ: IMRX
· Real-Time Price · USD
6.05
-0.48 (-7.35%)
At close: Oct 03, 2025, 3:59 PM
6.09
0.65%
After-hours: Oct 03, 2025, 07:56 PM EDT
-7.35% (1D)
| Bid | 6.05 |
| Market Cap | 219.63M |
| Revenue (ttm) | 726.33K |
| Net Income (ttm) | -62.13M |
| EPS (ttm) | -1.5 |
| PE Ratio (ttm) | -4.03 |
| Forward PE | -3.65 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 6.15 |
| Volume | 3,465,465 |
| Avg. Volume (20D) | 1,577,117 |
| Open | 6.58 |
| Previous Close | 6.53 |
| Day's Range | 6.02 - 6.88 |
| 52-Week Range | 1.10 - 10.08 |
| Beta | 0.47 |
| Ex-Dividend Date | n/a |
About IMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-13.33%
Immuneering shares are trading lower after the com...
Unlock content with
Pro Subscription
1 week ago
+7.45%
Immuneering shares are trading higher after the company reported 86% overall survival at 9 months in first-line pancreatic cancer patients treated with Atebimetinib plus mGnP.
